Browse drugs

…n their ILD by 24 months. Sixty-nine (93.2%) were on IS (mainly MMF) at time of HRCTs. Twenty-eight patients (37.8%) presented at l…

… found a negative correlation level of IL-13 with total dose of cyclophosphamide (R=-0.248 (p<0.05)).Conclusions Our dates indirectly confirm th…

…nts on corticosteroid therapy at doses higher than 10 mg/day of prednisone(or equivalent),with active infections or malignancies,were excl…

…D study ( NCT05878717) is evaluating the efficacy and safety of belimumab in patients with SSc-ILD; it will be important to assess the re…

…=0.01), total lung capacity (p=0.01) and diffusing capacity for carbon monoxide (p=0.004), although these associations did not remain significa…

…ohort B included 39 patients, of whom 53.8% tested positive for ACA, 41% for anti-SCL 70 antibodies, and 5.1% for anti-RNA polymera…

… hypertension, and rare scleroderma-specific antibodies (Th/To, fibrillarin).Notably, the distribution of first non-RP manifestations diffe…

…re, which was associated with swallowing at risk of aspiration. EAT-10 might be useful PRO for screening aspiration in SSc.…

…=0.56), C-reactive protein (p=0.67), serum albumin (p=0.72) and corticosteroid use (p=1).Conclusions Our findings confirm that dysphagia is hi…

…esophageal involvement (78% vs 34%, p=0.001), reflux and use of proton pump inhibitors (71% vs 40% and 85% vs 56%, p=0.016 and 0.015, respectively) an…

…s prevalent in 90% of patients. The most common ANA pattern was Anti-centromere present in 50% of patients, Speckled in 20% and Nucleolar in 20…

…hat the presence of CC was associated with an increasing use of Iloprost (H 3.73, 95% CI: 1.35-10.36, p=0.011), but not of ERA, PDE5i or…